INTRODUCTION AND OBJECTIVES: Salvage surgery is an option for recurrent prostate cancer(PCa) after focal therapy (FT). This is the first study to assess the impact of FT on surgical outcomes comparing salvage robotic-assisted radical prostatectomy(S-RARP) versus primary-RARP(P-RARP). We aimed to compare the impact of FT on perioperative, oncological and functional outcomes in men underwent S-RARP versus P-RARP.
INTRODUCTION AND OBJECTIVES: Salvage surgery is an option for recurrent prostate cancer(PCa) after focal therapy (FT) . This is the first study to assess the impact of FT on surgical outcomes comparing salvage robotic-assisted radical prostatectomy(S-RARP) versus primary-RARP(P-RARP). We aimed to compare the impact of FT on perioperative, oncological and functional outcomes in men underwent S-RARP versus P-RARP.
METHODS: Prospective data of 2775 men underwent RARP for localized PCa from 2000 to 2016 were reviewed. Twenty-five men underwent S-RARP after FT failure(S-RARP group). Total 2750 underwent RARP as primary treatment. Matched-pair 1:2 selection of 44 out of 2750 patients by age, IPSS and IIEF5 defined P-RARP group. Primary endpoint was between-groups differences on functional outcomes. Secondary endpoint was oncological data. p<0.05 was significant.
RESULTS: Surgical time, transfusion and complication rates were comparable(p!0.05). Rates of continence probability[49.5%(SE 0.13) versus 62.4%(SE 0.08), p¼0.8 and 73%(SE 0.14) versus 76.5%(SE 0.07), p¼0.8, at 1 and 2 years, respectively] and the chance for achieving continence[HR 1.062, 95%CI 0.54-2.08, p¼0.861] were comparable between-groups. Potency recovery was significant lower on S-RARP at 1 year follow-up[3AE2 versus 9.22AE6.55, p¼0.008]. S-RARP showed significant lower rates of cumulative 
INTRODUCTION AND OBJECTIVES:
Recent findings from the ProtecT trial suggest that survival in clinically localised prostate cancer is very high, and that radical treatments half the incidence of metastatic disease progression but at the cost of significant side effects. Using minimally invasive technology, such as HIFU or cryotherapy, for partial gland ablation (PA) could reduce these side effects. Partial prostate Ablation versus Radical prostatectomy (PART trial) is the first phase III study to compare PA and radical surgery (RP) in intermediate risk prostate cancer. PART is a prospective, multi-centre, parallel group randomised controlled trial to assess the clinical effectiveness and costutility of PA or RP in patients with intermediate risk, unilateral clinically significant localised prostate cancer. Our hypothesis is that PA of the prostate using minimally invasive therapies can achieve organ preservation, reduce side effects, maintain good voiding and sexual function, without compromise to oncological outcomes. We report the outcomes of our successful feasibility study which will now drive the establishment of the main multi-centre randomised controlled trial.
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